Key result
Bosentan significantly reduced systolic blood pressure (177 vs 197 mm Hg; P<0.01) and attenuated vascular hypertrophy and remodeling in DOCA-salt hypertensive rats.
Why the study?
Does bosentan reduce blood pressure and vascular hypertrophy in DOCA-salt hypertensive rats?
Does bosentan reduce blood pressure and vascular hypertrophy in DOCA-salt hypertensive rats?
Absolute Event Rate: 177% vs 197%
p-value: p=< .01
Bosentan reduces blood pressure and vascular hypertrophy in DOCA-salt hypertensive rats, highlighting the role of endothelin in hypertension-related vascular remodeling.
No takes yet. Share an insight, caveat, or question.
Should not change clinical hypertension practice; hypothesis-generating for endothelin antagonism in vascular remodeling.
Li et al. (1994) studied DOCA-salt hypertension. Bosentan vs. Untreated DOCA-salt hypertensive rats was evaluated on Systolic blood pressure (p=< .01). Bosentan significantly reduced systolic blood pressure (177 vs 197 mm Hg; P<0.01) and attenuated vascular hypertrophy and remodeling in DOCA-salt hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: